← Leaderboards
Guillermo A Morales
Signalrx Pharmaceuticals, Inc.
$2,567,895
Attributed
$2,567,895
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$2,567,895 · 3
By mechanism
R42$1,968,269 · 1
R43$299,888 · 1
R41$299,738 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Mission”
- Kelly K Wismer · Department Of Defense$358,750,224
- Valerie Koch · University Corporation For Atmospheric Res$265,601,376
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- John E West · University Of Texas At Austin$131,399,667
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Lisa Garcia Bedolla · University Of California-Berkeley$82,631,880
Research focus
MissionPublic HealthLeadMalignant NeoplasmsPathway InteractionsPhosphotransferasesIndustryInnovationDisabilityMalignant Childhood NeoplasmGenetic TranscriptionNovel TherapeuticsAnalogPharmaceutical PreparationsAdultBaseCellsInhibitor/AntagonistAcademiaCollaborationsComputer SimulationDesign1-Phosphatidylinositol 3-KinaseResistance
Grant awards (4)
Overcoming BTK inhibitor resistance in B-cell malignancies$299,888
R43 · FY2019 · CA · contact PI
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523$647,711
R42 · FY2018 · CA · contact PI
Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity$299,738
R41 · FY2018 · CA · contact PI
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523$1,320,558
R42 · FY2017 · CA · contact PI